HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Dr. Patrick C. Roche

Senior Vice President of Research & Development

Dr. Christina M. Carruthers Ph.D.

Vice President of Target Strategy & Early Development

Ms. Laura Lee Godlewski

Senior Vice President of Finance & Administration

Mr. John L. Lubniewski

President, Chief Executive Officer & Director

Mr. Shaun D. McMeans

Senior Vice President, Chief Financial Officer, Secretary & Treasurer

Dr. Debra A. Gordon

Senior Vice President & Chief Legal Counsel

Dr. Stephen A. Barat Ph.D.

Senior Vice President of Therapeutics

Debrah  Thompson

Vice President of Scientific Innovation

Diagnostic et recherche

HTG Molecular Diagnostics, Inc.

HTG Molecular Diagnostics, Inc. Structure de gestion

Informations sur la direction